Souhaitez-vous accéder aux communiqués récents ?

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) indberetter hermed følgende transaktioner: 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnCarsten...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions: 1.Details of the person discharging managerial responsibility / person closely associateda)NameCarsten...

Bemærk venligst, at rapporten udelukkende findes på engelsk. ALK reports 52% tablet growth and 61% earnings growth in Q3 (unaudited) ALK’s revenue returned to growth in Q3 with 7% revenue growth as...

ALK reports 52% tablet growth and 61% earnings growth in Q3 (unaudited) ALK’s revenue returned to growth in Q3 with 7% revenue growth as sales across the tablet portfolio grew 52%, led by Europe and...

Bestyrelsen i ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) indstiller Gitte Pugholm Aabo, administrerende direktør i GN Hearing A/S og Bertil Lindmark, direktør for forskning og udvikling i Galecto A/S...

The Board of Directors at ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) is to nominate Gitte Pugholm Aabo, CEO of GN Hearing A/S and Bertil Lindmark, Chief Medical Officer of Galecto A/S as new,...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for de første ni måneder (Q3) 2020 onsdag den 11. november 2020. ALK afholder samme dag kl. 13.30 (CET) en telekonference for...

On Wednesday, 11 November 2020, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its nine-month interim report (Q3) 2020. ALK will host a meeting for analysts and institutional investors that...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at selskabets foreløbige resultater for tredje kvartal viser en organisk vækst i nettoomsætningen på 7 %, drevet af en stigning på 52 % i...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales. Therefore, the company...